211801-77-3

Upstream product

• 73-34-7 D-Fucose 
• 108-98-5 thiophenol 
• 100-39-0 benzyl bromide 
• 141193-62-6 Phenyl-2,3,4-tri-O-acetyl-6-desoxy-1-thio-β-D-galactopyranosid 

Downstream Products

• 1272526-45-0 2-(trimethylsilyl)ethyl-2,3,4-tri-O-benzyl-α-D-fucopyranosyl-(1-4)-6-O-benzyl-3-O-chloroacetyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-β-D-glucopyranoside 
• 1272526-20-1 2-(trimethylsilyl)ethyl-2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-(1-4)-[2,3,4-tri-O-benzyl-α-D-fucopyranosyl-(1-3)]-6-O-benzyl-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-β-D-glucopyranoside 
• 1272526-33-6 2-(trimethylsilyl)ethyl-2,3,4-tri-O-benzyl-α-D-fucopyranosyl-(1-3)-4,6-O-benzylidene-2-deoxy-2-(2,2,2-trichloroethoxycarbonylamino)-β-D-glucopyranoside 
• 1272526-56-3 2-(trimethylsilyl)ethyl-2,3,4-tri-O-benzyl-α-D-fucopyranosyl-(1-3)-[2,3,4-tri-O-benzyl-α-D-fucopyranosyl-(1-4)]-6-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranoside 
• 1002099-33-3 benzyl 2,3,4-tri-O-benzyl-6-deoxy-α-D-galactopyranosyl-(1,3)-2,4,6-tri-O-pivaloyl-β-D-galactopyranosyl-(1,4)-2,3,6-tri-O-pivaloyl-β-D-glucopyranoside 
• 478687-14-8 2,3,4-tri-O-benzyl-α-D-fucopyranosyl-(1->3)-2,4,6-tri-O-acetyl-β-D-galactopyranosyl-(1->4)-N-acetyl-2,3,6-tri-O-acetyl-β-D-glucopyranosylamine 
• 868258-69-9 (2R,3S,4R,5R,6R)-5-Azido-2-azidomethyl-6-[(1R,2S,3S,4R,6S)-4,6-diazido-2-hydroxy-3-((2R,3R,4S,5S,6R)-3,4,5-tris-benzyloxy-6-methyl-tetrahydro-pyran-2-yloxy)-cyclohexyloxy]-tetrahydro-pyran-3,4-diol 
• 958310-17-3 C₆₃H₇₈Cl₆N₂O₂₀Si 
• 478687-13-7 2,3,4-tri-O-benzyl-α-D-fucopyranosyl-(1->3)-2,4,6-tri-O-acetyl-β-D-galactopyranosyl-(1->4)-2,3,6-tri-O-acetyl-β-D-glucopyranosyl azide 

Relevant academic research and scientific papers

The synthesis of deoxy-α-Gal epitope derivatives for the evaluation of an anti-α-Gal antibody binding

α-Gal epitopes (also termed as α-Gal) are carbohydrate structures bearing the α-D-Gal-(1→3)-β-D-Gal terminus 1 and are known to be the antigen responsible for antibody-mediated hyperacute rejection in xenotransplantation. Terminal 2-, 3-, 4-, and 6-deoxy-Gal derivatives of α-Gal were synthesized. Inhibition ELISA using mouse laminin was established to determine the binding affinity of the synthesized α-Gal derivatives. 4-Deoxy-α-Gal derivative 7 showed a significant reduction in antibody recognition. The IC50 value was 15-fold poorer than the standard α-Gal epitopes α-D-Gal-(1→3)-β-D-Gal-(1→4)-β-D-Glc-NHAc (39) and α-D-Gal-(1→3)-β-D-Gal-(1→4)-β-D-Glc-OBn (40). A similar observation was seen with 2-deoxy-α-Gal derivative 5, whose IC50 value was nearly tenfold higher than the standards. Interestingly, substitution at the terminal 3-position resulted in only a fourfold decrease in antibody recognition, suggesting a possible point of future derivation. Finally, 6-deoxy-α-Gal derivative 8 exhibited similar antibody recognition to both α-Gal epitope 39 and α-Gal epitope 40. This strongly suggests that derivatization at the 6-position can be accomplished without loss of antibody recognition. These findings can be utilized for the future design of other α-Gal derivatives.